This finding underscores the central role of CD8+ TSCM cells in the pathophysiological mechanisms underlying depression, highlighting the potential of CXCR2 inhibitor as a therapeutic target for modulating T cell-mediated neuroinflammation. Here, CD8A is linked to depressive symptom measurement.